Valuation: 3SBio Inc.

Capitalization 54.33B 60.84B 7.8B 6.64B 6.15B 5.75B 10.71B 717B 11.36B 70.29B 27.91B 338B 29.26B 28.66B 1,231B P/E ratio 2025 *
5.56x
P/E ratio 2026 * 16.1x
Enterprise value 44.53B 49.88B 6.4B 5.44B 5.04B 4.71B 8.78B 588B 9.31B 57.62B 22.88B 277B 23.98B 23.49B 1,009B EV / Sales 2025 *
2.42x
EV / Sales 2026 * 3.6x
Free-Float
72.15%
Yield 2025 *
3.64%
Yield 2026 * 2.28%
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.67%
1 week-8.01%
Current month+0.74%
1 month-7.16%
3 months-10.18%
6 months-14.68%
Current year+0.74%
More quotes
1 week 23.62
Extreme 23.62
26.48
1 month 23.58
Extreme 23.58
29.3
Current year 23.58
Extreme 23.58
29.3
1 year 5.81
Extreme 5.81
36.8
3 years 4.91
Extreme 4.91
36.8
5 years 4.72
Extreme 4.72
36.8
10 years 4.72
Extreme 4.72
36.8
More quotes
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2006
Director of Finance/CFO - 03/07/2023
Corporate Officer/Principal 56 27/11/2014
Director TitleAgeSince
Chairman 63 03/04/2012
Director/Board Member 56 11/06/2012
Director/Board Member 57 01/06/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.67%-8.01%+290.38%+174.94% 7.8B
-0.26%+2.80%+8.48%+3.24% 77.31B
+0.68%+2.33%-33.47%-39.80% 59.49B
-0.58%-3.09%+40.04%+234.20% 57.5B
+1.35%+80.20%+80.20%+80.20% 56.95B
-1.27%+4.36%+19.43%-41.22% 25.17B
-2.92%-3.97%+40.62%+22.17% 20.02B
-6.09%+16.45%+14.91%-75.27% 19.03B
+2.83%-6.48%+164.45%+94.20% 18.62B
-2.55%+2.11%+109.95%+813.97% 15.01B
Average -0.71%-0.10%+73.50%+126.66% 35.69B
Weighted average by Cap. -0.32%-0.04%+39.50%+81.88%
See all sector performances

Financials

2025 *2026 *
Net sales 18.41B 20.62B 2.64B 2.25B 2.08B 1.95B 3.63B 243B 3.85B 23.82B 9.46B 115B 9.91B 9.71B 417B 11.49B 12.86B 1.65B 1.4B 1.3B 1.22B 2.27B 152B 2.4B 14.86B 5.9B 71.55B 6.19B 6.06B 260B
Net income 9.55B 10.7B 1.37B 1.17B 1.08B 1.01B 1.88B 126B 2B 12.36B 4.91B 59.5B 5.14B 5.04B 216B 3.3B 3.7B 474M 403M 374M 349M 651M 43.56B 690M 4.27B 1.7B 20.57B 1.78B 1.74B 74.82B
Net Debt -9.79B -10.97B -1.41B -1.2B -1.11B -1.04B -1.93B -129B -2.05B -12.67B -5.03B -61.01B -5.27B -5.17B -222B -12.98B -14.54B -1.86B -1.59B -1.47B -1.37B -2.56B -171B -2.71B -16.8B -6.67B -80.87B -6.99B -6.85B -294B
More financial data * Estimated data
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
6,268
More about the company
Date Price Change Volume
23/01/26 24.36 $ +1.67% 20,248,550
22/01/26 23.96 $ -4.16% 34,765,190
21/01/26 25.00 $ 0.00% 14,919,850
20/01/26 25.00 $ -0.08% 14,681,830
19/01/26 25.02 $ -5.51% 30,074,620

Delayed Quote Hong Kong S.E., 23 January 2026 at 07:08 pm AEDT

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.75CNY
Average target price
34.81CNY
Spread / Average Target
+60.05%
Consensus

Quarterly revenue - Rate of surprise